Stomach Cancer
FEATURES
avatar
1309 clinical trials
avatar
163 cell line models
avatar
11 approved drugs
IMAGE
Stomach Cancer
Molecular Synopsis
OVERVIEW
Drugs and clinical candidates

11 drugs have received FDA approval for Stomach Cancer:

  • Docetaxel
  • Doxorubicin Hydrochloride
  • Fluorouracil
  • Imatinib Mesylate
  • Mitomycin
More

242 drugs have a clinical trial registered for Stomach Cancer.

2192 compounds have been tested in Stomach Cancer (1391 <= 500nM potency).

Sources: cancer.gov, clinicaltrials.gov, ChEMBL.

Clinical trials
There are 1309 clinical trials for Stomach Cancer, 763 of which have one or more drug interventions, 546 with no drug intervention.
Cell line models

There are 163 Cell Line Models for Stomach Cancer.

Source: COSMIC
Cell line models

Please note the mappings below are based on an imperfect algorithm. If you notice any anomalies please report them to us.

The following terms have been mapped from clinicaltrials.gov mesh condition terms to Stomach Cancer:
  • Gastrointestinal Stromal Tumors
  • Sex Cord-Gonadal Stromal Tumors
  • Sarcoma, Endometrial Stromal
  • Stomach Neoplasms
  • Endometrial Stromal Tumors
The following terms have been mapped from cancer.gov to Stomach Cancer:
  • Stomach adenocarcinoma or gastroesophageal junction adenocarcinoma (a rare type of esophageal cancer) that is advanced or has metastasized (spread to other parts of the body). It is used in patients whose disease has gotten worse after treatment with a fluoropyrimidine or platinum chemotherapy. It is used alone or with paclitaxel
  • Gastric (stomach) cancer or gastroesophageal junction cancer that is recurrent and either locally advanced or metastatic. It is used in patients whose cancer has the PD-L1 protein and whose disease got worse during or after two or more types of treatment including a fluoropyrimidine and platinum chemotherapy and, in some cases, HER2/neu targeted therapy.????
  • Gastric (stomach) cancer
  • Stomach adenocarcinoma or gastroesophageal junction adenocarcinoma (a rare type of esophageal cancer) that has metastasized. It is used in patients whose disease is HER2+. This use is approved for the Herceptin and Ogivri brands of trastuzumab
  • Gastrointestinal stromal tumor (a type of stomach cancer). It is used in patients whose condition has become worse while taking imatinib mesylate or who are not able to take it
More